Literature DB >> 12888494

Intracellular mRNA cleavage by 3' tRNase under the direction of 2'-O-methyl RNA heptamers.

Masato Tamura1, Chikako Nashimoto, Noriko Miyake, Yasushi Daikuhara, Kozo Ochi, Masayuki Nashimoto.   

Abstract

Mammalian tRNA 3' processing endoribonuclease (3'-tRNase) can cleave any RNA at any site under the direction of small guide RNA (sgRNA) in vitro. sgRNAs can be as short as heptamers, which are much smaller than small interfering RNAs of approximately 21 nt. Together with such flexibility in substrate recognition, the ubiquity and the constitutive expression of 3'-tRNase have suggested that this enzyme can be utilized for specific cleavage of cellular RNAs by introducing appropriate sgRNAs into living cells. Here we demonstrated that the expression of chloramphenicol acetyltransferase can be downregulated by an appropriate sgRNA which is introduced into Madin-Darby canine kidney epithelial cells as an expression plasmid or a synthetic 2'-O-methyl RNA. We also showed that 2'-O-methyl RNA heptamers can attack luciferase mRNAs with a high specificity and induce 3'-tRNase-mediated knock-down of the mRNAs in 293 cells. Furthermore, the MTT cell viability assay suggested that an RNA heptamer can downregulate the endogenous Bcl-2 mRNA in Sarcoma 180 cells. This novel sgRNA/3'-tRNase strategy for destroying specific cellular RNAs may be utilized for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888494      PMCID: PMC169917          DOI: 10.1093/nar/gkg641

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  23 in total

1.  Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate.

Authors:  S M Elbashir; J Martinez; A Patkaniowska; W Lendeckel; T Tuschl
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

Review 2.  This is the end: processing, editing and repair at the tRNA 3'-terminus.

Authors:  H Schürer; S Schiffer; A Marchfelder; M Mörl
Journal:  Biol Chem       Date:  2001-08       Impact factor: 3.915

Review 3.  The power of ribozyme technologies: the logical way ahead for molecular medicine and gene therapy?

Authors:  Alexander C J Freelove; Richard Zheng
Journal:  Curr Opin Mol Ther       Date:  2002-10

Review 4.  Gene silencing in mammals by small interfering RNAs.

Authors:  Michael T McManus; Phillip A Sharp
Journal:  Nat Rev Genet       Date:  2002-10       Impact factor: 53.242

5.  Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs.

Authors:  S Wiemann; B Weil; R Wellenreuther; J Gassenhuber; S Glassl; W Ansorge; M Böcher; H Blöcker; S Bauersachs; H Blum; J Lauber; A Düsterhöft; A Beyer; K Köhrer; N Strack; H W Mewes; B Ottenwälder; B Obermaier; J Tampe; D Heubner; R Wambutt; B Korn; M Klein; A Poustka
Journal:  Genome Res       Date:  2001-03       Impact factor: 9.043

Review 6.  BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability.

Authors:  Tomasz Skorski
Journal:  Oncogene       Date:  2002-12-09       Impact factor: 9.867

7.  Minimum requirements for substrates of mammalian tRNA 3' processing endoribonuclease.

Authors:  M Nashimoto; M Tamura; R L Kaspar
Journal:  Biochemistry       Date:  1999-09-14       Impact factor: 3.162

Review 8.  Antisense oligonucleotides: promise and reality.

Authors:  I Lebedeva; C A Stein
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 9.  Antisense therapy for cancer--the time of truth.

Authors:  Burkhard Jansen; Uwe Zangemeister-Wittke
Journal:  Lancet Oncol       Date:  2002-11       Impact factor: 41.316

10.  Anomalous RNA substrates for mammalian tRNA 3' processing endoribonuclease.

Authors:  M Nashimoto
Journal:  FEBS Lett       Date:  2000-04-28       Impact factor: 4.124

View more
  12 in total

1.  A novel 4-base-recognizing RNA cutter that can remove the single 3' terminal nucleotides from RNA molecules.

Authors:  Hiroaki Takaku; Asako Minagawa; Masamichi Takagi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2004-06-28       Impact factor: 16.971

2.  The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity.

Authors:  Hiroaki Takaku; Asako Minagawa; Masamichi Takagi; Masayuki Nashimoto
Journal:  Nucleic Acids Res       Date:  2004-08-18       Impact factor: 16.971

Review 3.  TRUE Gene Silencing.

Authors:  Masayuki Nashimoto
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

4.  TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents.

Authors:  Arisa Haino; Tatsuya Ishikawa; Mineaki Seki; Masayuki Nashimoto
Journal:  J Vis Exp       Date:  2016-06-02       Impact factor: 1.355

5.  Elimination of specific miRNAs by naked 14-nt sgRNAs.

Authors:  Masayuki Takahashi; Reyad A Elbarbary; Mayumi Abe; Mari Sato; Tetsuo Yoshida; Yoji Yamada; Masato Tamura; Masayuki Nashimoto
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

6.  Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL.

Authors:  Yuichiro Habu; Naoko Miyano-Kurosaki; Michiko Kitano; Yumihiko Endo; Masakazu Yukita; Shigeru Ohira; Hiroaki Takaku; Masayuki Nashimoto; Hiroshi Takaku
Journal:  Nucleic Acids Res       Date:  2005-01-12       Impact factor: 16.971

7.  Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing.

Authors:  Satoshi Iizuka; Nobuhiko Oridate; Masayuki Nashimoto; Satoshi Fukuda; Masato Tamura
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

8.  Modulation of gene expression by human cytosolic tRNase Z(L) through 5'-half-tRNA.

Authors:  Reyad A Elbarbary; Hiroaki Takaku; Naoto Uchiumi; Hiroko Tamiya; Mayumi Abe; Masayuki Takahashi; Hiroshi Nishida; Masayuki Nashimoto
Journal:  PLoS One       Date:  2009-06-15       Impact factor: 3.240

9.  Optimization and characterization of tRNA-shRNA expression constructs.

Authors:  Lisa J Scherer; Richard Frank; John J Rossi
Journal:  Nucleic Acids Res       Date:  2007-04-10       Impact factor: 16.971

10.  Hints of tRNA-Derived Small RNAs Role in RNA Silencing Mechanisms.

Authors:  Maria Rosa Garcia-Silva; Florencia Cabrera-Cabrera; Maria Catalina Güida; Alfonso Cayota
Journal:  Genes (Basel)       Date:  2012-10-10       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.